Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression
Authors:
Open Access
- 12 November 2015
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (3) , 2462-2474
Abstract
Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expressionKeywords
This publication has 35 references indexed in Scilit:
- Targeting MYCN in Neuroblastoma by BET Bromodomain InhibitionCancer Discovery, 2013
- Smac Mimetic SM-164 Potentiates APO2L/TRAIL- and Doxorubicin-Mediated Anticancer Activity in Human Hepatocellular Carcinoma CellsPLOS ONE, 2012
- Targeting Epigenetic Readers in CancerNew England Journal of Medicine, 2012
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences of the United States of America, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Hepatocellular carcinoma pathogenesis: from genes to environmentNature Reviews Cancer, 2006
- Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liverOncogene, 1998